Multidisciplinary Approach to Reduce Cardiovascular Health Disparities
NCT ID: NCT06168968
Last Updated: 2024-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2023-02-06
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will engage in laboratory testing and health outcome assessments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Inflammation Reduction Trial
NCT01594333
Atherosclerosis in the Coronary and Carotid Arteries
NCT00080587
Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
NCT00438867
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
NCT04610892
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
NCT02525939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient
(Secondary Prevention) Includes black (n=150) and white (n=150) patients greater than or equal to 18 years of age hospitalized for acute coronary syndrome (ACS), multi-vessel disease, or ischemic stroke undergoing intervention
Life and Medication Recommendations
Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
Family Member
(Primary Prevention) Includes black subjects (n=75) who are first or second-degree relatives of patients in Cohort 1 and have no history of prior hospitalization for cardiovascular or cerebrovascular disease
Life and Medication Recommendations
Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Life and Medication Recommendations
Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Competent mental condition to provide informed consent and able to participate in follow-ups
Exclusion Criteria
* Currently enrolled in an investigational drug or device trial
* Undergoing treatment for neoplastic, autoimmune, or connective tissue disease
* COVID-19 infection within 30 days of enrollment
* Known history of hepatitis or HIV
* Deemed unfit to participate according to the investigator
* Known history of drug abuse
* Known platelet count of \<100,000/mm3
* Hematocrit \< 25%
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland
OTHER
LifeBridge Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul A. Gurbel
Director of Cardiovascular Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jenna Brager, PhD
Role: STUDY_CHAIR
LifeBridge Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Paul Gurbel, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1941089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.